Innate Pharma
IPHA
#8560
Rank
HK$0.93 B
Marketcap
HK$11.21
Share price
-11.66%
Change (1 day)
-41.63%
Change (1 year)

Revenue for Innate Pharma (IPHA)

Revenue in 2022: HK$0.41 Billion

According to Innate Pharma 's latest financial reports the company's current revenue (TTM ) is HK$0.41 Billion. In 2022 the company made a revenue of HK$0.41 Billion an increase over the revenue in the year 2021 that were of HK$0.10 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Innate Pharma from 2005 to 2022

Annual revenue

Year Revenue Change
2022HK$0.41 B287.78%
2021HK$0.10 B-80.14%
2020HK$0.53 B-10.13%
2019HK$0.59 B-15.91%
2018HK$0.71 B133.44%
2017HK$0.30 B-33.72%
2016HK$0.45 B201.72%
2015HK$0.15 B1674.86%
2014HK$8.58 M-93.59%
2013HK$0.13 B25.45%
2012HK$0.10 B41.8%
2011HK$75.36 M68.46%
2010HK$44.73 M-48.02%
2009HK$86.06 M-38.81%
2008HK$0.14 B-13.41%
2007HK$0.16 B86.54%
2006HK$87.07 M286.35%
2005HK$22.53 M